Patients who start antiretroviral therapy with a combination based on a “boosted” protease inhibitor are less likely to develop drug-resistant HIV than patients who take therapy based on either a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a non-boosted protease inhibitor, according to a large Canadian study published in the July 1st edition of the Journal of Infectious Diseases. The study also showed that the risk of resistance amongst patients starting anti-HIV treatment for the first time has fallen significantly in more recent years.
http://www.aidsmap.com/en/news/37187051-D8A1-4CDF-BA5C-387893C3EEB5.asp